Aerosol gemcitabine

Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs

Carlos O. Rodriguez, Torrie A. Crabbs, Dennis W Wilson, Virginia A. Cannan, Katherine A Skorupski, Nancy Gordon, Nadya Koshkina, Eugenie Kleinerman, Peter M. Anderson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Osteosarcoma is the most common skeletal malignancy in the dog and in young humans. Although chemotherapy improves survival time, death continues to be attributed to metastases. Aerosol delivery can provide a strategy with which to improve the lung drug delivery while reducing systemic toxicity. The purpose of this study is to assess the safety of a regional aerosol approach to chemotherapy delivery in osteosarcoma-bearing dogs, and second, to evaluate the effect of gemcitabine on Fas expression in the pulmonary metastasis. Methods: We examined the systemic and local effects of aerosol gemcitabine on lung and pulmonary metastasis in this relevant large-animal tumor model using serial laboratory and arterial blood gas analysis and histopathology and immunohistochemistry, respectively. Results and Conclusions: Six hundred seventy-two 1-h doses of aerosol gemcitabine were delivered. The treatment was well tolerated by these subjects with osteosarcoma (n = 20). Aerosol-treated subjects had metastatic foci that demonstrated extensive, predominately central, intratumoral necrosis. Fas expression was decreased in pulmonary metastases compared to the primary tumor (p = 0.008). After aerosol gemcitabine Fas expression in the metastatic foci was increased compared to lung metastases before treatment (p = 0.0075), and even was higher than the primary tumor (p = 0.025). Increased apoptosis (TUNEL) staining was also detected in aerosol gemcitabine treated metastasis compared to untreated controls (p = 0.028). The results from this pivotal translational study support the concept that aerosol gemcitabine may be useful against pulmonary metastases of osteosarcoma. Additional studies that evaluate the aerosol route of administration of gemcitabine in humans should be safe and are warranted.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalJournal of Aerosol Medicine and Pulmonary Drug Delivery
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

gemcitabine
Osteosarcoma
Aerosols
Dogs
Safety
Neoplasm Metastasis
Lung
Neoplasms
Drug Therapy
Blood Gas Analysis
In Situ Nick-End Labeling

Keywords

  • aerosol chemotherapy
  • dog model
  • gemcitabine
  • relapsed osteosarcoma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Pharmaceutical Science

Cite this

Aerosol gemcitabine : Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. / Rodriguez, Carlos O.; Crabbs, Torrie A.; Wilson, Dennis W; Cannan, Virginia A.; Skorupski, Katherine A; Gordon, Nancy; Koshkina, Nadya; Kleinerman, Eugenie; Anderson, Peter M.

In: Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 23, No. 4, 01.08.2010, p. 197-206.

Research output: Contribution to journalArticle

Rodriguez, Carlos O. ; Crabbs, Torrie A. ; Wilson, Dennis W ; Cannan, Virginia A. ; Skorupski, Katherine A ; Gordon, Nancy ; Koshkina, Nadya ; Kleinerman, Eugenie ; Anderson, Peter M. / Aerosol gemcitabine : Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. In: Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010 ; Vol. 23, No. 4. pp. 197-206.
@article{be56e353a9f8455bb1e613e159a4e610,
title = "Aerosol gemcitabine: Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs",
abstract = "Background: Osteosarcoma is the most common skeletal malignancy in the dog and in young humans. Although chemotherapy improves survival time, death continues to be attributed to metastases. Aerosol delivery can provide a strategy with which to improve the lung drug delivery while reducing systemic toxicity. The purpose of this study is to assess the safety of a regional aerosol approach to chemotherapy delivery in osteosarcoma-bearing dogs, and second, to evaluate the effect of gemcitabine on Fas expression in the pulmonary metastasis. Methods: We examined the systemic and local effects of aerosol gemcitabine on lung and pulmonary metastasis in this relevant large-animal tumor model using serial laboratory and arterial blood gas analysis and histopathology and immunohistochemistry, respectively. Results and Conclusions: Six hundred seventy-two 1-h doses of aerosol gemcitabine were delivered. The treatment was well tolerated by these subjects with osteosarcoma (n = 20). Aerosol-treated subjects had metastatic foci that demonstrated extensive, predominately central, intratumoral necrosis. Fas expression was decreased in pulmonary metastases compared to the primary tumor (p = 0.008). After aerosol gemcitabine Fas expression in the metastatic foci was increased compared to lung metastases before treatment (p = 0.0075), and even was higher than the primary tumor (p = 0.025). Increased apoptosis (TUNEL) staining was also detected in aerosol gemcitabine treated metastasis compared to untreated controls (p = 0.028). The results from this pivotal translational study support the concept that aerosol gemcitabine may be useful against pulmonary metastases of osteosarcoma. Additional studies that evaluate the aerosol route of administration of gemcitabine in humans should be safe and are warranted.",
keywords = "aerosol chemotherapy, dog model, gemcitabine, relapsed osteosarcoma",
author = "Rodriguez, {Carlos O.} and Crabbs, {Torrie A.} and Wilson, {Dennis W} and Cannan, {Virginia A.} and Skorupski, {Katherine A} and Nancy Gordon and Nadya Koshkina and Eugenie Kleinerman and Anderson, {Peter M.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1089/jamp.2009.0773",
language = "English (US)",
volume = "23",
pages = "197--206",
journal = "Journal of Aerosol Medicine and Pulmonary Drug Delivery",
issn = "1941-2711",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Aerosol gemcitabine

T2 - Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs

AU - Rodriguez, Carlos O.

AU - Crabbs, Torrie A.

AU - Wilson, Dennis W

AU - Cannan, Virginia A.

AU - Skorupski, Katherine A

AU - Gordon, Nancy

AU - Koshkina, Nadya

AU - Kleinerman, Eugenie

AU - Anderson, Peter M.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Background: Osteosarcoma is the most common skeletal malignancy in the dog and in young humans. Although chemotherapy improves survival time, death continues to be attributed to metastases. Aerosol delivery can provide a strategy with which to improve the lung drug delivery while reducing systemic toxicity. The purpose of this study is to assess the safety of a regional aerosol approach to chemotherapy delivery in osteosarcoma-bearing dogs, and second, to evaluate the effect of gemcitabine on Fas expression in the pulmonary metastasis. Methods: We examined the systemic and local effects of aerosol gemcitabine on lung and pulmonary metastasis in this relevant large-animal tumor model using serial laboratory and arterial blood gas analysis and histopathology and immunohistochemistry, respectively. Results and Conclusions: Six hundred seventy-two 1-h doses of aerosol gemcitabine were delivered. The treatment was well tolerated by these subjects with osteosarcoma (n = 20). Aerosol-treated subjects had metastatic foci that demonstrated extensive, predominately central, intratumoral necrosis. Fas expression was decreased in pulmonary metastases compared to the primary tumor (p = 0.008). After aerosol gemcitabine Fas expression in the metastatic foci was increased compared to lung metastases before treatment (p = 0.0075), and even was higher than the primary tumor (p = 0.025). Increased apoptosis (TUNEL) staining was also detected in aerosol gemcitabine treated metastasis compared to untreated controls (p = 0.028). The results from this pivotal translational study support the concept that aerosol gemcitabine may be useful against pulmonary metastases of osteosarcoma. Additional studies that evaluate the aerosol route of administration of gemcitabine in humans should be safe and are warranted.

AB - Background: Osteosarcoma is the most common skeletal malignancy in the dog and in young humans. Although chemotherapy improves survival time, death continues to be attributed to metastases. Aerosol delivery can provide a strategy with which to improve the lung drug delivery while reducing systemic toxicity. The purpose of this study is to assess the safety of a regional aerosol approach to chemotherapy delivery in osteosarcoma-bearing dogs, and second, to evaluate the effect of gemcitabine on Fas expression in the pulmonary metastasis. Methods: We examined the systemic and local effects of aerosol gemcitabine on lung and pulmonary metastasis in this relevant large-animal tumor model using serial laboratory and arterial blood gas analysis and histopathology and immunohistochemistry, respectively. Results and Conclusions: Six hundred seventy-two 1-h doses of aerosol gemcitabine were delivered. The treatment was well tolerated by these subjects with osteosarcoma (n = 20). Aerosol-treated subjects had metastatic foci that demonstrated extensive, predominately central, intratumoral necrosis. Fas expression was decreased in pulmonary metastases compared to the primary tumor (p = 0.008). After aerosol gemcitabine Fas expression in the metastatic foci was increased compared to lung metastases before treatment (p = 0.0075), and even was higher than the primary tumor (p = 0.025). Increased apoptosis (TUNEL) staining was also detected in aerosol gemcitabine treated metastasis compared to untreated controls (p = 0.028). The results from this pivotal translational study support the concept that aerosol gemcitabine may be useful against pulmonary metastases of osteosarcoma. Additional studies that evaluate the aerosol route of administration of gemcitabine in humans should be safe and are warranted.

KW - aerosol chemotherapy

KW - dog model

KW - gemcitabine

KW - relapsed osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=77955449671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955449671&partnerID=8YFLogxK

U2 - 10.1089/jamp.2009.0773

DO - 10.1089/jamp.2009.0773

M3 - Article

VL - 23

SP - 197

EP - 206

JO - Journal of Aerosol Medicine and Pulmonary Drug Delivery

JF - Journal of Aerosol Medicine and Pulmonary Drug Delivery

SN - 1941-2711

IS - 4

ER -